AN2 테라퓨틱스(ANTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $5.05 (+3.06%), 시가총액 $0.18B, 52주 최저~최고 $1.03 ~ $5.46.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It ha
AN2 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
AN2 테라퓨틱스의 현재 주가는 $5.05 (+3.06%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
AN2 테라퓨틱스의 시가총액은 약 $0.18B입니다.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 cl